Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12081
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGallagher, Martinen
dc.contributor.authorCass, Alanen
dc.contributor.authorBellomo, Rinaldoen
dc.contributor.authorFinfer, Simonen
dc.contributor.authorGattas, Daviden
dc.contributor.authorLee, Joanneen
dc.contributor.authorLo, Serigneen
dc.contributor.authorMcGuinness, Shayen
dc.contributor.authorMyburgh, Johnen
dc.contributor.authorParke, Rachaelen
dc.contributor.authorRajbhandari, Dorrilynen
dc.date.accessioned2015-05-16T01:43:39Z
dc.date.available2015-05-16T01:43:39Z
dc.date.issued2014-02-11en
dc.identifier.citationPLoS Medicine 2014; 11(2): e1001601en
dc.identifier.govdoc24523666en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12081en
dc.description.abstractThe incidence of acute kidney injury (AKI) is increasing globally and it is much more common than end-stage kidney disease. AKI is associated with high mortality and cost of hospitalisation. Studies of treatments to reduce this high mortality have used differing renal replacement therapy (RRT) modalities and have not shown improvement in the short term. The reported long-term outcomes of AKI are variable and the effect of differing RRT modalities upon them is not clear. We used the prolonged follow-up of a large clinical trial to prospectively examine the long-term outcomes and effect of RRT dosing in patients with AKI.We extended the follow-up of participants in the Randomised Evaluation of Normal vs. Augmented Levels of RRT (RENAL) study from 90 days to 4 years after randomization. Primary and secondary outcomes were mortality and requirement for maintenance dialysis, respectively, assessed in 1,464 (97%) patients at a median of 43.9 months (interquartile range [IQR] 30.0-48.6 months) post randomization. A total of 468/743 (63%) and 444/721 (62%) patients died in the lower and higher intensity groups, respectively (risk ratio [RR] 1.04, 95% CI 0.96-1.12, p = 0.49). Amongst survivors to day 90, 21 of 411 (5.1%) and 23 of 399 (5.8%) in the respective groups were treated with maintenance dialysis (RR 1.12, 95% CI 0.63-2.00, p = 0.69). The prevalence of albuminuria among survivors was 40% and 44%, respectively (p = 0.48). Quality of life was not different between the two treatment groups. The generalizability of these findings to other populations with AKI requires further exploration.Patients with AKI requiring RRT in intensive care have high long-term mortality but few require maintenance dialysis. Long-term survivors have a heavy burden of proteinuria. Increased intensity of RRT does not reduce mortality or subsequent treatment with dialysis.www.ClinicalTrials.govNCT00221013.en
dc.language.isoenen
dc.subject.otherAcute Kidney Injury.diagnosis.mortality.therapyen
dc.subject.otherAgeden
dc.subject.otherAlbuminuria.mortality.therapyen
dc.subject.otherAustraliaen
dc.subject.otherChi-Square Distributionen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherIntensive Care Unitsen
dc.subject.otherKaplan-Meier Estimateen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherMultivariate Analysisen
dc.subject.otherNew Zealanden
dc.subject.otherOdds Ratioen
dc.subject.otherPrevalenceen
dc.subject.otherProportional Hazards Modelsen
dc.subject.otherProspective Studiesen
dc.subject.otherRenal Dialysis.adverse effects.mortalityen
dc.subject.otherRisk Factorsen
dc.subject.otherSurvivorsen
dc.subject.otherTime Factorsen
dc.subject.otherTreatment Outcomeen
dc.titleLong-term survival and dialysis dependency following acute kidney injury in intensive care: extended follow-up of a randomized controlled trial.en
dc.typeJournal Articleen
dc.identifier.journaltitlePLoS Medicineen
dc.identifier.affiliationThe George Institute for Global Health, Sydney, Australia ; University of Sydney, Sydney, Australiaen
dc.identifier.affiliationThe George Institute for Global Health, Sydney, Australia ; Menzies School of Health Research, Darwin, Australiaen
dc.identifier.affiliationThe George Institute for Global Health, Sydney, Australia ; St. George Clinical School, University of New South Wales, Sydney, Australiaen
dc.identifier.affiliationThe George Institute for Global Health, Sydney, Australia ; Royal Prince Alfred Hospital, Camperdown, Australiaen
dc.identifier.affiliationAustin Hospital, Heidelberg, Australiaen
dc.identifier.affiliationThe George Institute for Global Health, Sydney, Australiaen
dc.identifier.affiliationAuckland City Hospital, Auckland, New Zealand.en
dc.identifier.doi10.1371/journal.pmed.1001601en
dc.description.pagese1001601en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24523666en
dc.contributor.corpauthorPOST-RENAL Study Investigators and the ANZICS Clinical Trials Groupen
dc.type.austinJournal Articleen
local.name.researcherBellomo, Rinaldo
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.